0001213900-22-017645.txt : 20220404 0001213900-22-017645.hdr.sgml : 20220404 20220404061752 ACCESSION NUMBER: 0001213900-22-017645 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20220404 DATE AS OF CHANGE: 20220404 GROUP MEMBERS: ELIYAHU YORESH GROUP MEMBERS: LIRON CARMEL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: FUEL DOCTOR HOLDINGS, INC. CENTRAL INDEX KEY: 0001459188 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MOTOR VEHICLE SUPPLIES & NEW PARTS [5013] IRS NUMBER: 262274999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-93616 FILM NUMBER: 22800323 BUSINESS ADDRESS: STREET 1: 410 LOUISIANA STREET CITY: VALLEJO STATE: CA ZIP: 94590 BUSINESS PHONE: 707-373-3031 MAIL ADDRESS: STREET 1: 410 LOUISIANA STREET CITY: VALLEJO STATE: CA ZIP: 94590 FORMER COMPANY: FORMER CONFORMED NAME: Silverhill Management Services Inc DATE OF NAME CHANGE: 20090320 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Medigus Ltd. CENTRAL INDEX KEY: 0001618500 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 3 HANECHOSHET STREET, BUILDING B CITY: TEL AVIV STATE: L3 ZIP: 6971068 BUSINESS PHONE: 972722602211 MAIL ADDRESS: STREET 1: 3 HANECHOSHET STREET, BUILDING B CITY: TEL AVIV STATE: L3 ZIP: 6971068 SC 13D 1 ea157149-13dmedigus_fueldoc.htm SCHEDULE 13D

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

 

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.__)*

 

Fuel Doctor Holdings, Inc.
(Name of Issuer)

 

Common Stock, par value $0.0001 per share   35953U 106
(Title of class of securities)   (CUSIP number)

 

Tali Dinar

3 HaNechoshet Street, building B

Tel Aviv, Israel, 6971068

Tel: +972-73-370-4691
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

January 7, 2022
(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13(d)-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the reminder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following pages)
(Page 1 of 8 Pages)

 

 

 

 

 

 

CUSIP No. 35953U 106

 

1

NAME OF REPORTING PERSON:                      Medigus Ltd.

 

I.R.S. IDENTIFICATION NO.

OR ABOVE PERSON (ENTITIES ONLY):

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a) ☒

(b) ☐

3

SEC Use Only

 

4

SOURCE OF FUNDS:

 

WC

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e):

 

6

CITIZENSHIP OR PLACE OF ORGANIZATION:

 

Israel

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7

SOLE VOTING POWER:

 

90,000,000

8

SHARED VOTING POWER:

 

0

9

SOLE DISPOSITIVE POWER:

 

90,000,000

10

SHARED DISPOSITIVE POWER:

 

0

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON:

 

90,000,000

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

 

35.06% (1)

14

TYPE OF REPORTING PERSON:

 

CO

 

(1)The percentage set forth in row (13) is based on 256,739,363 shares of common stock, par value $0.0001 per share, on November 10, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2021.

 

2 

 

 

CUSIP No. 35953U 106 

 

1

NAME OF REPORTING PERSON:                      Eliyahu Yoresh (1)

 

I.R.S. IDENTIFICATION NO.

OR ABOVE PERSON (ENTITIES ONLY):

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a) ☒

(b) ☐

3

SEC Use Only

 

4

SOURCE OF FUNDS:

 

WC

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e):

 

6

CITIZENSHIP OR PLACE OF ORGANIZATION:

 

Israel

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7

SOLE VOTING POWER:

 

12,000,000

8

SHARED VOTING POWER:

 

90,000,000

9

SOLE DISPOSITIVE POWER:

 

12,000,000

10

SHARED DISPOSITIVE POWER:

 

90,000,000

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON:

 

102,000,000 (2)

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

 

39.73% (3)

14

TYPE OF REPORTING PERSON:

 

IN

 

(1)Eliyahu Yoresh is the Chairman of the Board of Directors of Medigus Ltd. (“Medigus”) and therefore may be deemed a beneficial owner of any shares of Common Stock beneficially owned by Medigus.

 

(2)Consists of (a) 12,000,000 shares of Common Stock beneficially owned directly by Eliyahu Yoresh, and (b) 90,000,000 shares of Common Stock beneficially owned by Medigus, in which Mr. Yoresh serves as its Chairman of the Board of Directors. To the extent Mr. Yoresh is deemed to beneficially own such shares of Common Stock beneficially owned by Medigus, Mr. Yoresh disclaims beneficial ownership of these securities for all other purposes.

 

(3)The percentage set forth in row (13) is based on 256,739,363 shares of common stock, par value $0.0001 per share (the “Common Stock”), on November 10, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2021.

 

3 

 

 

CUSIP No. 35953U 106

 

1

NAME OF REPORTING PERSON:                      Liron Carmel (1)

 

I.R.S. IDENTIFICATION NO.

OR ABOVE PERSON (ENTITIES ONLY):

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a) ☒

(b) ☐

3

SEC Use Only

 

4

SOURCE OF FUNDS:

 

WC

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e):

 

6

CITIZENSHIP OR PLACE OF ORGANIZATION:

 

Israel

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7

SOLE VOTING POWER:

 

6,725,000

8

SHARED VOTING POWER:

 

90,000,000

9

SOLE DISPOSITIVE POWER:

 

6,725,000

10

SHARED DISPOSITIVE POWER:

 

90,000,000

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON:

 

96,725,000 (2)

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

 

37.68% (3)

14

TYPE OF REPORTING PERSON:

 

IN

 

(1)Liron Carmel is the Chief Executive Officer of Medigus and therefore may be deemed a beneficial owner of any shares of Common Stock beneficially owned by Medigus.

 

(2)Consists of (a) 6,725,000 shares of Common Stock beneficially owned directly by Liron Carmel, and (b) 90,000,000 shares of Common Stock beneficially owned by Medigus, in which Mr. Carmel serves as Chief Executive Officer. To the extent Mr. Carmel is deemed to beneficially own such shares of Common Stock beneficially owned by Medigus, Mr. Carmel disclaims beneficial ownership of these securities for all other purposes.

 

(3)The percentage set forth in row (13) is based on 256,739,363 shares of common stock, par value $0.0001 per share, on November 10, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2021.

 

4 

 

 

Item 1. Security and Issuer

 

This statement on Schedule 13D (this “Statement”) relates to the common stock, par value $0.0001 per share (“Common Stock”) of Fuel Doctor Holdings, Inc., a company incorporated under the laws of the State of Delaware (the “Issuer”). According to the most recent Quarterly Report on Form 10-Q of the Issuer, filed with the Securities and Exchange Commission on November 11, 2021, the principal executive offices of the Issuer are located at 410 Louisiana Street, Vallejo, CA 94590.

 

Item 2.

Identity and Background.

 

(a)-(b) Medigus Ltd., a company organized under the laws of the State of Israel (“Medigus”), is a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions. The address of its principal office and principal place of business is 3 HaNechoshet Street, building B, Tel Aviv, Israel, 6971068.

 

As of the date of this Schedule, Eliyahu Yoresh, an Israeli citizen, is the Chairman of the Board of Directors of Medigus.

 

As of the date of this Schedule, Liron Carmel, an Israeli citizen, is the Chief Executive Officer of Medigus.

 

Collectively, Medigus, Mr. Yoresh and Mr. Carmel are hereinafter referred to as the “Reporting Persons”.

 

(c) The names, business addresses, present principal occupation or employment (and names, principal businesses and addresses of places of additional employment) and citizenship of the executive officers and directors of Medigus are set forth in Annex A hereto and incorporated herein by reference.

 

(d)-(e) None of the Reporting Persons nor, to the best of its knowledge, any of Medigus’ respective executive officers and directors listed on Annex A hereto, have during the last five years (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.

Source and Amount of Funds or Other Consideration.

 

The aggregate amount of funds used by Medigus in acquiring 90,000,000 shares of Common Stock referred to in Item 5 below (the “Shares”) was US$262,500 (US$0.0029 per Share). The source of the funds used to purchase such shares is the working capital of Medigus.

 

The aggregate amount of funds used by Mr. Yoresh in acquiring 12,000,000 shares of Common Stock referred to in Item 5 below (the “Shares”) was US$34,500 (US$0.0028 per Share). The source of the funds used to purchase such shares is the working capital of Mr. Yoresh.

 

The aggregate amount of funds used by Mr. Carmel in acquiring 6,725,000 shares of Common Stock referred to in Item 5 below (the “Shares”) was US$19,500 (US$0.0028 per Share). The source of the funds used to purchase such shares is the working capital of Mr. Carmel.

 

5 

 

 

Item 4.

Purpose of Transaction.

 

The Reporting Persons purchased the Shares because it plans to cause the Issuer to identify, evaluate and investigate various companies with the intent that, if such investigation warrants, a reverse merger transaction be negotiated and completed pursuant to which the Issuer would acquire a target company with an operating business, with the intent of continuing the acquired company’s business as a publicly held entity. The Issuer has limited capital with which to provide the owners of the target company with any significant cash or other assets and, as such, the Issuer will only be able to offer owners of a target company the opportunity to acquire a controlling ownership interest in the Issuer.

 

In addition, subject to applicable law, the Reporting Persons specifically reserves the right to discuss with other shareholders and the Issuer matters that may be of common concern. No agreements, arrangements or understandings exist between the Reporting Persons and third parties with respect to the foregoing.

 

Except as set forth in this Item 4, neither the Reporting Persons nor, to the best knowledge of the Reporting Persons, any of the persons set forth on Annex A, has any present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Person specifically reserves the right to adopt and pursue one or more such plans, and to make such proposals, at any time and from time to time in the future.

 

Item 5.

Interest in Securities of the Issuer.

 

(a)-(b) Medigus is the direct beneficial owner of 90,000,000 shares of Common Stock or approximately 35.06% of the outstanding capital stock of the Issuer, based on 256,739,363 shares of Common Stock, on November 10, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2021 (the “Issuer’s Report”).

 

Eliyahu Yoresh is the direct beneficial owner of 12,000,000 shares of Common Stock or approximately 4.67% of the outstanding capital stock of the Issuer, based on 256,739,363 shares of Common Stock as disclosed in the Issuer’s Report.

 

Liron Carmel is the direct beneficial owner of 6,725,000 shares of Common Stock or approximately 2.62% of the outstanding capital stock of the Issuer, based on 256,739,363 shares of Common Stock as disclosed in the Issuer’s Report.

 

Except for the foregoing, to the best knowledge of the Reporting Person, none of the persons set forth on Annex A beneficially owns any securities of the Issuer.

 

(c) Other than the purchase of 90,000,000 shares of Common Stock on January 7, 2022 in a private transaction as reported herein, Medigus has not effected any transaction in the Common Stock during the past 60 days.

 

Other than the purchase of 12,000,000 shares of Common Stock on January 7, 2022 in a private transaction as reported herein, Mr. Yoresh has not effected any transaction in the Common Stock during the past 60 days.

 

Other than the purchase of 6,725,000 shares of Common Stock on January 7, 2022 in a private transaction as reported herein, Mr. Carmel has not effected any transaction in the Common Stock during the past 60 days.

 

(d) Not applicable.

 

(e) Not applicable.

 

6 

 

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

Except as set forth below, there are no present contracts, arrangements, understandings or relationships (legal or otherwise) between Medigus, or, to the best knowledge of the Reporting Person, any of the persons set forth on Annex A, and any other person with respect to the securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangement, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies:

 

(a)Eliyahu Yoresh, Chairman of the Board of Directors of Medigus, beneficially owns 12,000,000 shares of Common Stock as of the date of this Schedule 13D.

 

(b)Liron Carmel, Chief Executive Officer of Medigus, beneficially owns 6,725,000 shares of Common Stock as of the date of this Schedule 13D.

 

Item 7.

Material to be Filed as Exhibits.

 

Exhibit 1 Joint Filing Agreement by and among Medigus Ltd., Eliyahu Yoresh and Liron Carmel, dated April 4, 2022
Exhibit 2 Stock Purchase Agreement

 

7 

 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certify that the information set forth in this Statement is true, complete and correct.

 

  MEDIGUS LTD.
     
  By: /s/ Tali Dinar
    Tali Dinar
    Chief Financial Officer
     
  April 4, 2022
     
  ELIYAHU YORESH
     
  By: /s/ Eliyahu Yoresh
    Eliyahu Yoresh
     
  April 4, 2022
     
  LIRON CARMEL
     
  By: /s/ Liron Carmel
    Liron Carmel
     
  April 4, 2022

 

8 

EX-99.1 2 ea157149ex99-1_fueldoctor.htm JOINT FILING AGREEMENT BY AND AMONG MEDIGUS LTD., ELIYAHU YORESH AND LIRON CARMEL, DATED APRIL 4, 2022

Exhibit 1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of common stock, par value $0.0001 per share, of Fuel Doctor Holdings, Inc., a company incorporated under the laws of the State of Delaware. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.

 

  MEDIGUS LTD.
     
  By: /s/ Tali Dinar
    Tali Dinar
    Chief Financial Officer
     
  April 4, 2022
     
  ELIYAHU YORESH
     
  By: /s/ Eliyahu Yoresh
    Eliyahu Yoresh
     
  April 4, 2022
     
  LIRON CARMEL
     
  By: /s/ Liron Carmel
    Liron Carmel
     
  April 4, 2022

 

 

 

 

ANNEX A

 

Executive Officers and Directors of Medigus Ltd.

 

Set forth below is the name, current business address, the present principal occupation or employment and citizenship of each director and executive officer of Medigus Ltd. (“Medigus”). Unless otherwise indicated, each person identified below is employed by Medigus. The principal address of Medigus, and unless otherwise indicated below, the current business address for each individual listed below, is 3 HaNechoshet Street, building B, Tel Aviv, Israel, 6971068.

 

 

Name, Position with Medigus and Business Address

  Present Principal Occupation or Employment   Citizenship
Liron Carmel, Chief Executive Officer   Chief Executive Officer of Medigus Ltd.   Israel
Tali Dinar, Chief Financial Officer   Chief Financial Officer of Medigus Ltd.   Israel
Eliyahu Yoresh, Chairman of the Board of Directors   Financial and Executive Consulting Services, Self-Employed   Israel
Eli Cohen, Director   Attorney, Self-Employed   Israel
Ronen Rosenbloom, Director   Attorney, Self-Employed   Israel
Kineret Tzedef, Director   Director of Sports Division, Hapoel   Israel

 

 

 

 

 

EX-99.2 3 ea157149ex99-2_fueldoctor.htm STOCK PURCHASE AGREEMENT

Exhibit 2

 

STOCK PURCHASE AGREEMENT

 

THIS AGREEMENT is made and entered into this 30th day of December 2021, by and among Fuel Doctor Holdings, Inc. (the “Seller”), Medigus Ltd. together with other similar purchasers (the “Purchaser”, and collectively, the “Purchasers”) and Fuel Doctor Holdings Inc. (the “Company”).

 

AGREEMENT

 

In consideration of the terms hereof, the parties hereto agree as follows:

 

1. PURCHASE AND SALE OF STOCK

 

1.1 Purchase and Sale of Stock. Upon the terms and subject to the conditions herein, the Seller hereby sells, conveys, transfers, assigns and delivers to the Purchasers a total of 108,725,000 shares of the Company’s common stock, par value US$0.0001 (the “Common Stock and the “Purchased Shares”, respectively). Each Purchaser shall purchase such number of the Purchased Shares as is set forth next to their name on the signature pages hereto. The Purchased Shares are represented by Company stock certificates number 1537, 1540 and 1559.

 

1.2 Purchase Price. Subject to the terms and conditions of this Agreement, the aggregate purchase price for all of the Purchased Shares shall be $279,000.00, payable at Closing and payable in such amounts by the respective Purchasers opposite each Purchaser’s name on the signature page hereto.

 

1.3 The Closing. The closing of this Agreement (the “Closing”) shall occur remotely on or about December 8, 2021 (the “Closing Date”) at 10:00 a.m. local time.

 

1.4 Deliveries at the Closing. On the Closing Date (or such date set forth below) and in order to effectuate the sale, conveyance, transfer, assignment and delivery of the Purchased Shares to the Purchasers, the following conditions must be met:

 

(a) Prior to the Closing, the Seller shall deliver, to Paul Goodman, Esq. (the “Document Escrow Agent”), to be held in escrow, (i) a stock power duly executed in blank attached in the form attached hereto as Schedule A bearing a medallion guaranty stamp and an instruction letter to the Company’s transfer agent to transfer the Purchased Shares in to the name of the Purchaser, or its designees, (ii) resignation letters of each officer and director of the Company in the form attached hereto as Schedule “B”, and (iii) a Good Standing Certificate of the Company issued by the Secretary of State of the State of Delaware, dated no more than 30 days prior to the Closing Date.

 

(b) Purchasers shall deliver the Purchase Price, in their respective amounts, to the Seller, by wire transfer.

 

(c) Seller shall deliver to the Purchasers a list providing a full corporate history of the Company, starting on the original date of incorporation and include all the changes that have occurred through the Closing Date, including, but not limited to the following: changes of corporate control (via shareholder vote and/or with consent of prior officers), Share Exchange/Purchase Agreements, reverse merger transactions, custodianships, corporation reorganizations, reinstatement of the certificate of incorporation, change of the start of incorporation, appointment of a conservator, and bankruptcies (including confirmation that bankruptcy proceedings are no longer active).

 

 

 

 

(d) Seller shall deliver to the Purchasers a file-stamped copy of the original articles of incorporation from the Company’s original state of incorporation and each subsequent file-stamped articles of amendment for each name change through the current name, and articles of conversion into the Company’s current state of incorporation, Delaware

 

(e) All instruments and documents executed and delivered to any party pursuant hereto shall be in a form and substance, and shall be executed in a manner, reasonably satisfactory to the receiving party.

 

1.5 Assistance in Consummation of the Purchase and Sale of Purchased Shares. The Seller and Purchaser each shall provide all reasonable assistance to, and shall cooperate with, each other to bring about the consummation of the purchase and sale of the Purchased Shares as soon as possible in accordance with the terms and conditions of this Agreement. Each party shall be responsible for any regulatory filings, if any, for which such party is obligated to file as a result of the transaction contemplated herein.

 

2. REPRESENTATIONS AND WARRANTIES OF THE SELLER AND THE COMPANY

 

As of the date hereof and as of the Closing Date, the Company and the Seller each represent and warrant, severally and jointly, to the Purchasers as follows:

 

2.1 Good Title. The Purchased Shares are and shall be free and clear of any claim, lien, pledge, option, charge, easement, security interest, right-of-way, encumbrance, restriction on sale or transfer, preemptive right or option or any other right of any third party of any nature whatsoever. The Purchased Shares are being held in certificate form. The Purchased Shares represent 42.2% of the stock capital of the Company on a fully diluted basis.

 

2.2 Consents and Approvals. There is no requirement to make any filing, give any notice to or obtain any license, permit, certificate, regulation, authorization, consent or approval of, any governmental or regulatory authorities as a condition to the lawful consummation of the transactions contemplated by this Agreement.

 

2.3 Organization, Good Standing. The Company is a corporation, duly formed, validly existing and in good standing under the laws of the State of Delaware, and has all requisite corporate power and authority to own, operate and lease its properties and assets and to carry on its business as now conducted.

 

2

 

 

2.4 Subsidiaries and Affiliates. The Company has no subsidiaries other than Fuel Doctor LLC.

 

2.5 No Liabilities. The Company have no liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) which exceed $5,000. The Company has no outstanding or unsatisfied judgments, orders, decrees or stipulations to which the Company is a party.

 

2.6 Contracts. Other than this Agreement, the Company is not a party to any contract or agreement, written oral.

 

2.7 Taxes. The Company and its subsidiaries (if applicable) has filed all federal, state, county and local income, excise, property and other tax, governmental and/or related returns, forms, or reports, which are due or required to be filed by it prior to the Closing Date, and has paid all taxes, fees, or assessments which have or may become due pursuant to such returns or pursuant to any assessments received. The Company is not delinquent or obligated for any tax, penalty, interest, delinquency or charge.

 

Each such tax return or report has been duly filed on a timely basis and all such returns and reports are correct and complete in all material respects and fully discloses and does not understate the income, taxes, expenses, deductions and credits for the period to which it relates. Up to and including the Closing Date, no claim has been made against the Company by any authority in a jurisdiction in which it does not file a return that it is or may be subject to any taxes in that jurisdiction. The Company has not received notice of any actions, suits, proceedings, investigations or claims pending or threatened against the Company in respect of any taxes nor are any matters relating to any taxes under discussion with any governmental authority.

 

The Company has withheld from each payment made to any of its past or present employees, officers and directors or to any other person in respect of whom withholding therefrom is required, the amount of all taxes and other deductions required to be withheld therefrom and has paid the same to the proper tax authorities or other receiving officers in all material respects within the time required under any applicable legislation. The Company has collected all taxes it is required to collect and has remitted all such taxes it is required to remit to the proper tax authority when required to do so all.

 

2.8 Securities Matters.

 

(a) The Company’s Common Stock is currently registered pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as of the Closing, Company will have filed all reports, schedules, forms, statements and other documents required to be filed by it with the Commission pursuant to the reporting requirements of the Exchange Act (all of the foregoing including filings incorporated by reference therein being referred to herein as the “Commission Documents”).

 

3

 

 

(b) No form 10-Q, 8-K or Form 10-K filings as filed with the SEC by Company (collectively, “SEC Reports”) contains an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the SEC Reports complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the Commission or other applicable rules and regulations with respect thereto. The financial statements contained in the SEC Reports (the “Financial Statement”) have been prepared in accordance with generally accepted accounting principles applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in the Financial Statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the consolidated financial position of Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). The Financial Statements are complete, accurate and fairly present the financial condition of Company as of the dates thereof and the results of its operations for the periods then ended. There are no liabilities or obligations either fixed or contingent not reflected therein. Company is in substantial compliance with the applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder that are effective as of the Closing Date.

 

(c) The Company’s common stock is listed for quotation on the OTC Markets Board under the symbol “FDOC”. There are no stop orders in effect or contemplated with respect thereto and no facts exist which may give rise thereto. The Company has not been informed, and has no reason to believe, that the Company’s Common Stock will be delisted or suspended by FINRA. The Company’s Common Stock is “DTC eligible’ and the Company has not received any notice regarding any loss or suspension of its “DTC eligibility.’ There is no set of facts which create any impediment to approval by FINRA of the Company’s planned post-closing name change and reverse common stock split.

 

2.8 Litigation. Company is not a party to or the subject of any pending or threatened litigation, claims, decrees, orders, arbitration, alternate dispute resolutions proceedings, stipulations or governmental investigation or other proceeding not reflected in the Financial Statements or otherwise disclosed herein, and there are no lawsuits, claims, assessments, investigations, or similar matters pending or threatened against or affecting Company or its properties. Company has complied in all material respects with all laws, statutes, ordinances, regulations, rules, decrees or orders applicable to it. There are no outstanding orders, judgments, injunctions, awards or decrees of any court, arbitrator or governmental or regulatory body against Company, its officers or directors.

 

2.9 Claims and Proceedings. (a) There are no claims, actions, suits, arbitrations, proceedings or investigations involving, pending or, to the knowledge of the Company, threatened against the Company before or by any court or governmental or non-governmental department, commission, board, bureau, agency or instrumentality, or any other Person, which could question the validity of this Agreement or which could enjoin, restrain, condition or prohibit any action taken or to be taken by the Company pursuant to this Agreement or in connection with the transactions contemplated hereby and, there is no valid basis for any such claim, action, suit, arbitration, proceeding or investigation. There are no outstanding or unsatisfied judgments, orders, decrees, or stipulations by the Company is bound which involve or affect the transactions contemplated hereby.

 

4

 

 

(b) Company has not breached, nor is there any pending, or to the knowledge of management, any threatened claim that Company has breached, any of the terms or conditions of any agreements, contracts or commitments to which it is a party or by which it or its assets are is bound. The execution and performance hereof will not violate any provisions of applicable law or any agreement to which Company is subject. Company hereby represents that it has no business operations or material assets and it is not a party to any material contract or commitment other than appointment documents with its transfer agent, and that it has disclosed to Company all relationships or dealings with related parties or affiliates.

 

2.10 No Obligations to Issue Shares. There are no existing options, calls, warrants, preemptive rights or commitments of any character relating to the issued or unissued capital stock or other securities of Company and there exist no liens or other securities interests in any assets of Company.

 

2.11 No Preferred Stock Issued. The Company has no shares of any series of series of preferred stock issued and outstanding.

 

2.12 No Material Adverse Effects. Since September 30, 2021, Company has not experienced or suffered any Material Adverse Effect, and no event or circumstance has occurred or exists with respect to Company or its businesses, properties, prospects, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by Company but which has not been so publicly announced or disclosed. For the purposes of this Agreement, the term “Material Adverse Effect” means a material adverse effect on the business, financial condition, operations, results of operations, assets or future prospects of the Company.

 

2.13 Books and Records. The corporate financial records, minute books, and other documents and records of the Company shall be delivered to new management of the Company at Closing, with any shipping or delivery costs paid by the Company and Purchaser, and are correct and accurate in all material respects and reflect all decisions made by the Board of Directors and the stockholders of the Company.

 

2.14 Disclosure. All disclosure information provided by the Company to the Purchaser for use in connection with the transaction described herein is true, complete and accurate in all material respects. Neither this Agreement nor any other document furnished by or on behalf the Company in connection with the transactions contemplated by this Agreement contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made herein or therein, in the light of the circumstances under which they were made herein or therein, not misleading.

 

2.15 Employees. The Company has no employees.

 

2.16 Indemnification. For a period of one (1) year from the Closing, the Company and the Seller (an “Indemnifying Party”), jointly and severally agree to indemnify and hold harmless the Purchaser, against and in respect of any liability, damage or deficiency, all actions, suits, proceedings, demands, assessments, judgments, costs and expenses, including attorney’s fees incident to any of the foregoing, resulting from any material misrepresentations made by an Indemnifying Party, an Indemnifying Party’s breach of covenant or warranty or an Indemnifying Party’s non-fulfillment of any obligation hereunder.

 

5

 

 

3. ESCROWS

 

3.1 Document Escrow Agent. The Document Escrow Agent, shall receive and hold (a) the stock power described in Section 1.4(a) above, and (b) the resignation letters described in Section 1.4(c) above (collectively, the “Escrowed Documents”). Upon receipt of the Escrowed Documents, the Document Escrow Agent shall review such documents to determine such compliance with the terms of this Agreement and upon a determination that the Escrowed Documents are in compliance thereof, shall notify the Payment Escrow Agent, as identified on the signature page hereto. Upon notification (a) from the Payment Escrow Agent, that the Disbursement Escrow funds have been properly disbursed and (b) from the Seller that the Purchase Price has been received, the Document Escrow Agent shall distribute the Escrowed Documents to the parties entitled to receive such documents pursuant to the terms hereof.

 

4. GENERAL

 

4.1 Notices. Any notice under this Agreement shall be deemed to have been sufficiently given if sent by registered or certified mail, postage prepaid or national overnight carrier, addressed to a party at the address set forth on the signature page hereto or addresses ay hereafter be designated by either party by notice given in such manner. All notices shall be deemed to have been given as of the date of receipt.

 

4.2 Counterparts. This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall be an original, and all such counterparts shall constitute one and the same instrument. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original thereof.

 

4.3 Prior Agreements; Amendments. This Agreement supersedes all prior agreements and understandings between the parties with respect to the subject matter hereof. This Agreement may be amended only by a written instrument duly executed by the parties hereto or their respective successors or assigns.

 

4.4 Governing Law. This Agreement is to be construed in accordance with and governed by the laws of the State of Delaware. The parties hereto consent and agree that in the event any litigation is required to be commenced for the purpose of enforcing, interpreting or otherwise involving this Agreement and the transactions contemplated hereunder, that such litigation shall only be commenced in a court of competent jurisdiction located in New York County, New York and the parties hereby consent to the jurisdiction of any such court.

 

6

 

 

4.5 Expenses. Purchasers shall pay and be solely responsible for all fees and expenses incurred in connection with the transactions contemplated by this Agreement, except that Seller shall be responsible for its own legal fees and for all income taxes incurred in connection with the sale.

 

4.6 Parties in Interest. All the terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of, and shall be enforceable by the prospective heirs, beneficiaries, representatives, successors, and assigns of the parties hereto.

 

4.7 Headings. The section and paragraph headings contained in this agreement are for reference purposes only and shall not affect in any way the meaning or interpretations of this Agreement.

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed the day and year first above written.

 

(** Signature Pages Follow **)

 

7

 

 

SELLER SIGNATURE PAGE

 

    SELLER
     
    /s/ Joseph Passalaqua
    Joseph Passalaqua

 

8

 

 

ESCROW AGENT SIGNATURE PAGE

 

  Expense Disbursement Escrow Agent
  (solely as to Section 3)
 
   
   
  Document Escrow Agent
  (solely as to Section 3)
 
   

 

9

 

 

PURCHASERS SIGNATURE PAGE

 

  PURCHASER
  Medigus Ltd.
     
  By:
  Purchase Price (USD): 262,500
  Issued Shares: 90,000,000
     
  PURCHASER
  Eli Yoresh
     
  By: /s/ Eli Yoresh
  Purchase Price (USD): 34,500
  Issued Shares: 12,000,000
     
  PURCHASER
  Liron Carmel
     
  By: /s/ Liron Carmel
  Purchase Price (USD): 19,500
  Issued Shares: 6,750,000

 

10

 

 

SCHEDULE A

STOCK POWER

 

11

 

 

SCHEDULE B

RESIGNATION LETTERS

 

 

12

 

 

 

 

GRAPHIC 4 ex99-2_001.jpg GRAPHIC begin 644 ex99-2_001.jpg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end GRAPHIC 5 ex99-2_002.jpg GRAPHIC begin 644 ex99-2_002.jpg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